Patient Assistance Programs
 
Fighting AIDS in Africa
 
Bristol-Myers Squibb Foundation & Corporate Philanthropy
 
Product Integrity
 
Sustainability: Our Plan for Responsible Growth
 
Environment, Health & Safety Policy
 
Medical Education Grants And Charitable Contributions
 
Clinical Outcomes And Research Grants
 
Position On Key Issues
 
Clinical Trial Communication Commitment
Commitment to Highest Ethical Standards
Commitment to Medicare Beneficiaries
Direct-To-
Consumer Communications Code
PhRMA Annual Report
Policy On Stockholder Rights Plan
Political Contributions
Sustaining Our Intellectual Property
U.S. Health Care Reform

 

  » BMS.com Home » Corporate Responsibility » Position on Key Issues » Health Care Reform
SEARCH INDEX
 





U.S. Health Care Reform

Bristol-Myers Squibb supports accessible and affordable health care and measures to reduce the number of uninsured, especially vulnerable populations such as children and people with lower incomes, with the goal of achieving universal, continuous, and affordable health care coverage.

We support market-based policy approaches to reduce significantly the number of uninsured that build on the current public-private mix of health insurance coverage, while preserving incentives for innovation.

We have collaborated with and will continue to collaborate with other organizations to achieve accessible and affordable health care coverage.

For more information, please see Expanding Access to Medicines and Health Care: Compassion for Patients and Pharmaceutical Issues – Bristol-Myers Squibb Perspectives and Policies.

 

 

 




[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Atripla is a trademark of Bristol-Myers Squibb & Gilead Sciences, LLC. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

 

SEARCH INDEX